# Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection

> **NCT04629287** · PHASE1 · UNKNOWN · sponsor: **Kunming Pharmaceuticals, Inc.** · enrollment: 102 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** KPCXM18
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04629287
- **Lead sponsor:** Kunming Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11
- **Primary completion:** 2021-12
- **Final completion:** 2022-02
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629287, "Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04629287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*